未知生产厂商
CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.
CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.
CMLVAX100 is a BCR-ABL peptide vaccine designed to reduce persistent disease in patients with chronic myeloid leukemia (CML) whom have had stable disease during conventional therapy. Targeting the BCR-ABL breakpoint with vaccine based medicines is an important approach to those with detectable CML. Breakthrough has optimized the components of VAX100 to enhance its activity.
Investigated for use/treatment in leukemia (myeloid).
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
